Revenue
2012
2013
2015
2016
2017
2018
2019
2020
Phio Pharmaceuticals Corp. (PHIO)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $21,000 | $138,000 | $15,000 | $19,000 | $34,000 | — | $399,000 | $97,000 | — | — | — | — | — | — | — | — | — |
| Research & development | $4.6M | $3.6M | $6.3M | $7.0M | $8.9M | $3.7M | $4.3M | $4.3M | $5.4M | $5.4M | $6.9M | $5.7M | $17.7M | $3.7M | $6.2M | — | — | — | — | — | — | — | — |
| Operating expenses | $9.2M | $7.4M | $10.8M | $11.5M | $13.5M | $8.8M | $9.0M | $7.5M | $14.1M | $9.0M | $10.3M | $8.9M | $21.3M | $13.1M | — | — | — | — | — | — | — | — | — |
| Operating income | −$9.2M | −$7.4M | −$10.8M | −$11.5M | −$13.5M | −$8.8M | −$9.0M | −$7.4M | −$14.1M | −$9.0M | −$10.2M | −$8.8M | −$20.9M | −$13.0M | −$12.8M | — | — | — | — | — | — | — | — |
| EBITDAderived | −$9.2M | −$7.4M | −$10.8M | −$11.4M | −$13.4M | −$8.7M | −$8.9M | −$7.3M | −$14.0M | −$9.0M | −$10.2M | −$8.7M | −$20.9M | −$12.8M | −$12.6M | — | — | — | — | — | — | — | — |
| Net income | −$8.7M | −$7.2M | −$10.8M | −$11.5M | −$13.3M | −$8.8M | −$8.9M | −$7.4M | −$12.5M | −$9.0M | −$10.2M | −$8.8M | −$20.9M | −$12.9M | −$2.5M | −$12.0M | −$18.4M | −$14.4M | −$11.0M | −$2.4M | −$2.2M | −$3.3M | −$89,000 |
| Basic EPSper diluted share | -$1.45 | -$9.08 | -$46.76 | -$10.10 | -$12.43 | -$1.92 | -$19.33 | -$57.46 | -$5.52 | -$16.41 | -$2.10 | -$0.79 | -$2.88 | -$5.62 | -$0.28 | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | — | -$9.08 | -$46.76 | -$10.10 | -$12.43 | -$1.92 | -$19.33 | -$57.46 | -$5.52 | -$16.41 | -$2.10 | -$0.79 | -$2.88 | -$5.62 | -$0.28 | — | — | — | — | — | — | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 26, 2026Form 4 | Bitterman Robert JChairman, Pres. & CEO | BuyCommon Stock, $.0001 par value | 10.0K | $0.99 | $9.9K | 421.4K |
| Dec 31, 2025Form 4 | Bitterman Robert JChairman, Pres. & CEO | BuyCommon Stock, $.0001 par value | 5.0K | $1.03 | $5.2K | 291.4K |
| Dec 23, 2025Form 4 | Bitterman Robert JChairman, Pres. & CEO | BuyCommon Stock, $.0001 par value | 5.0K | $1.02 | $5.1K | 286.4K |
| Nov 21, 2025Form 4 | Bitterman Robert JChairman, Pres. & CEO | BuyCommon Stock, $.0001 par value | 5.0K | $1.14 | $5.7K | 281.4K |
| Nov 18, 2025Form 4 | Bitterman Robert JChairman, Pres. & CEO | BuyCommon Stock, $.0001 par value | 5.0K | $1.27 | $6.3K | 276.4K |